KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xenon Pharmaceuticals (XENE) Non Operating Investment Income (2019 - 2022)

Historic Non Operating Investment Income for Xenon Pharmaceuticals (XENE) over the last 4 years, with Q2 2022 value amounting to -$1.3 million.

  • Xenon Pharmaceuticals' Non Operating Investment Income fell 747647.06% to -$1.3 million in Q2 2022 from the same period last year, while for Jun 2022 it was -$4.7 million, marking a year-over-year decrease of 108229.43%. This contributed to the annual value of -$719000.0 for FY2021, which is 1807500.0% down from last year.
  • Latest data reveals that Xenon Pharmaceuticals reported Non Operating Investment Income of -$1.3 million as of Q2 2022, which was down 747647.06% from -$3.4 million recorded in Q1 2022.
  • Xenon Pharmaceuticals' 5-year Non Operating Investment Income high stood at -$17000.0 for Q2 2021, and its period low was -$3.4 million during Q1 2022.
  • Its 4-year average for Non Operating Investment Income is -$841833.3, with a median of -$177500.0 in 2020.
  • As far as peak fluctuations go, Xenon Pharmaceuticals' Non Operating Investment Income soared by 7366.55% in 2021, and later tumbled by 747647.06% in 2022.
  • Over the past 4 years, Xenon Pharmaceuticals' Non Operating Investment Income (Quarter) stood at -$29000.0 in 2019, then plummeted by 868.97% to -$281000.0 in 2020, then surged by 93.95% to -$17000.0 in 2021, then tumbled by 7476.47% to -$1.3 million in 2022.
  • Its Non Operating Investment Income was -$1.3 million in Q2 2022, compared to -$3.4 million in Q1 2022 and -$17000.0 in Q2 2021.